Table 1.

Patient and disease characteristics as recorded at time of FES PET scan, and clinical outcomes (n=90).

	N (%)
Age
<50 years	26 (29%)
≥ 50 years	64 (71%)
Sex
Female	88 (98%)
Male	2 (2%)
Menopausal status
Pre-menopausal	14 (16%)
Post-menopausal/male	76 (84%)
Time since breast cancer diagnosis
<2 months	22 (24%)
2 months - 5 years	31 (34%)
>5 years	37 (41%)
Primary tumor PgR
Positive or weakly positive	72 (80%)
Negative	14 (16%)
Not assessed	4 (4%)
Histology of primary breast cancer
Ductal	66 (73%)
Lobular	17 (19%)
Ductal and lobular	6 (7%)
Unknown	1 (1%)
Visceral disease at time of scan
Liver, lung, stomach lesion(s)	14 (16%)
No liver, lung, stomach lesion(s)	76 (84%)
Endocrine therapy following FES PET
Aromatase inhibitor	56 (62%)
Aromatase inhibitor + fulvestrant	20 (22%)
Tamoxifen	9 (10%)
Ovarian suppression only	2 (2%)
Fulvestrant	2 (2%)
Unknown	1 (1%)
Progression-free survival
Events	67 (74%, range 1-50 months)
Censored	23 (26%, range 0-54 months)
Overall survival
Events (deaths)	57 (63%, range 5-128 months)
Censored	33 (37%, range 3-130 months)
Clinical benefit
PFS > 6 months	47 (52%, 60% of assessed)
PFS ≤ 6 months	31 (34%)
Not assesseda	12 (13%)
	mean (standard deviation), range
FES dynSUV	2.73 (1.80), 0.50-9.62
FES SULmean3b	1.80 (1.35), 0.17-6.67
FES SUVmax3b	2.84 (1.79), 0.57-8.79
FDG SULmax3b	3.69 (2.43), 0.77-15.16
FDG SUVmax3b	5.78 (3.74), 1.25-22.95
FES/FDG ratio3c	0.92 (0.29), 0.34-1.71

^a7 patients had surgery or chemotherapy within 6 months of FES PET scan and without disease progression; 5 others were lost to follow-up within 6 months of FES PET scan

^bFES SULmean3 = $2\left[\frac{{\Sigma }_1^{n_i}{\mathit{log}}_2\left(\mathrm{FES}\mathrm{SULmean}\right)}{n_i}\right]$, geometric mean for up to 3 lesions in torso sweep with highest FDG SUVmax. Others are similarly constructed geometric means.

^cFES/FDG ratio3 = ${\sum }_1^{n_i}\left(\sqrt{\frac{\mathrm{FES}\mathrm{SUVmax}}{\mathrm{FDG}\mathrm{SUVmax}}}\right)∕n_i$, average of square root of measure for up to 3 lesions in torso sweep with highest FDG SUVmax

PgR progesterone receptor

PFS progression-free survival

FES dynSUV average of FES SUVmean of up to 3 lesions in the dynamic field of view